Boston, MA – September 24 – Apex BioTherapeutics has announced the development of Pepe-167, a synthetic 14-amino-acid research peptide inspired by bioactive compounds associated with New Zealand’s ancient native frogs, commonly known in Māori as pepeketua.
According to the company, the experimental peptide was modeled using biological information associated with Leiopelma hochstetteri, or Hochstetter’s frog, one of New Zealand’s distinctive native amphibian species.
The designation Pepe-167 refers to the compound’s position within Apex BioTherapeutics’ internal peptide optimization program.
Researchers are studying the molecule for its potential effects on cellular resilience, metabolic function and biological pathways associated with aging.
Inspiration From an Ancient Amphibian Lineage
New Zealand’s Leiopelma frogs belong to an unusually ancient amphibian lineage. Fossil relatives of the group extend back tens of millions of years, earning the animals frequent descriptions as evolutionary “living fossils.”
The frogs also possess several unusual biological characteristics. Unlike many modern frogs, they do not undergo a conventional free-swimming tadpole stage. Some species exhibit parental care behaviors, while their skin and physiology have adapted to the cool and demanding environments in which they live.
These characteristics attracted the attention of researchers interested in understanding biological mechanisms that allow organisms to tolerate environmental and cellular stress.
Rather than attempting to harvest material directly from wild frogs, researchers used biological sequence information and synthetic peptide engineering to design a laboratory-produced analog.
Apex says Pepe-167 is completely synthetic and is intended to reproduce selected biological properties identified during the research process while providing greater stability and suitability for laboratory investigation.
How Pepe-167 Is Being Studied
Apex BioTherapeutics describes Pepe-167 as a multi-pathway research compound rather than a molecule targeting a single biological mechanism.
Researchers are examining several pathways associated with cellular aging and metabolic health.
Sirtuin activity
Laboratory experiments are investigating whether Pepe-167 can influence SIRT1 and SIRT3, NAD+-dependent enzymes involved in mitochondrial function, cellular stress responses and DNA maintenance.
Autophagy
The peptide is also being evaluated for its potential influence on autophagy, the process cells use to remove and recycle damaged proteins and cellular components.
Researchers are examining interactions involving pathways such as mTOR and ULK1.
Telomere protection
Another area of investigation involves oxidative stress affecting telomeres, the protective structures located at the ends of chromosomes.
Researchers are studying whether Pepe-167 could reduce certain forms of cellular stress associated with telomere degradation.
AMPK signaling
Pepe-167 is additionally being examined for its interaction with AMPK, an important cellular energy-sensing pathway associated with glucose utilization, fatty-acid metabolism and overall energy balance.
NAD+ metabolism
The research program is also evaluating whether exposure to the peptide can influence intracellular NAD+ concentrations. NAD+ plays an important role in cellular energy production and several enzyme systems associated with mitochondrial function.
Early Laboratory Findings
According to preliminary data reported by Apex BioTherapeutics, experiments involving cultured human dermal fibroblasts, skeletal muscle cells and hepatocytes produced several potentially interesting results.
The company reports that cells exposed to Pepe-167 demonstrated improved survival under experimentally induced stress conditions.
Researchers also reported reductions in certain markers associated with cellular senescence, including p16 and p21, alongside changes in mitochondrial membrane potential.
These findings remain preclinical and require considerably more research before conclusions can be drawn regarding their relevance to human health or aging.
Cellular and Metabolic Research
Apex says additional laboratory experiments have examined Pepe-167 across several different biological models.
In aged human cell models, researchers reported increased production of collagen type I as well as increased hyaluronic-acid synthesis.
Adipocyte experiments were used to investigate potential metabolic effects. According to the company’s preliminary findings, cells treated with the experimental peptide showed reduced lipid accumulation and increased insulin-stimulated glucose uptake.
Researchers have also examined inflammatory signaling.
In stressed macrophage models, experiments reportedly demonstrated reduced expression of inflammatory cytokines including IL-6 and TNF-α.
Another early area of research involves neuronal cells. Preliminary laboratory experiments are investigating whether Pepe-167 may influence cellular resistance to oxidative stress and markers associated with synaptic health.
These experiments remain exploratory.
From Evolutionary Biology to Synthetic Peptides
The broader objective behind Pepe-167 is to investigate whether biological adaptations found in unusual organisms can provide templates for new synthetic molecules.
Instead of directly using naturally occurring compounds as therapeutics, researchers can identify potentially interesting molecular structures and then engineer synthetic versions optimized for stability, manufacturing and laboratory investigation.
This approach has increasingly become an area of interest within biotechnology as researchers examine animals, plants and microorganisms that have developed unusual adaptations to environmental stress.
Pepe-167 represents Apex BioTherapeutics’ attempt to apply that strategy to the biology of New Zealand’s ancient frog lineages.
Preclinical Development Continues
Pepe-167 remains an experimental research peptide and has not been established as an anti-aging treatment for humans.
Apex BioTherapeutics says the compound is progressing through expanded preclinical investigation, including pharmacokinetic research and safety toxicology studies.
Future experiments are expected to examine how the molecule behaves inside living biological systems, how long it remains active and whether the effects observed in isolated cells can be reproduced in more complex models.
The company also plans to make Pepe-167 available to qualified academic and industry researchers through controlled research agreements.
Independent replication will be necessary to determine whether the early findings reported by the company can be reproduced by outside laboratories.
A New Direction for Longevity Research
Research into biological aging increasingly focuses on maintaining cellular function rather than attempting to identify a single mechanism responsible for aging.
Mitochondrial dysfunction, impaired autophagy, chronic inflammation, metabolic changes, declining NAD+ availability and cellular senescence are among the interconnected processes being investigated across the longevity field.
Pepe-167 is being developed as a research tool for examining several of these processes simultaneously.
Whether the compound ultimately produces meaningful therapeutic applications remains unknown. The current findings represent early-stage laboratory research rather than evidence of efficacy in humans.
For now, the project provides another example of how researchers are looking toward some of Earth’s oldest surviving biological lineages for clues that could help scientists better understand cellular resilience and healthy aging.
About Apex BioTherapeutics
Apex BioTherapeutics describes itself as a Boston-based biotechnology company focused on bio-inspired peptide research.
Its research strategy examines biological survival mechanisms found throughout nature and uses those observations as starting points for engineering synthetic compounds.
The company says its research pipeline includes experimental candidates focused on aging biology, metabolic dysfunction and neurodegenerative conditions.
Media and Scientific Inquiries
For media inquiries, research collaboration opportunities, scientific data requests or information regarding laboratory access to Pepe-167:
press@apexbt.com
